Effectiveness of aprepitant in post-acute COVID19 syndrome
This is the first case of a patient taking aprepitant for a post-acute COVID-19 syndrome. This case may encourage researchers to look for the evidence for the efficacy and safety of a neurokinin 1 receptor antagonist in this frequent syndrome
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Universidad de Sevilla (US) |
| Repositorio: | idUS. Depósito de Investigación de la Universidad de Sevilla |
| OAI Identifier: | oai:idus.us.es:11441/137770 |
| Acceso en línea: | https://hdl.handle.net/11441/137770 https://doi.org/10.1002/ccr3.4646 |
| Access Level: | acceso abierto |
| Palabra clave: | Aprepitant Post-acute COVID19 SARS-CoV-2 |
| Sumario: | This is the first case of a patient taking aprepitant for a post-acute COVID-19 syndrome. This case may encourage researchers to look for the evidence for the efficacy and safety of a neurokinin 1 receptor antagonist in this frequent syndrome |
|---|